Navigation Links
Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
Date:8/18/2009

in the recently FDA cleared Phase I REGEN trial utilizing muscle derived stem cells transduced to express the SDF-1 protein.

The appointment of this team will enable Mr. Leonhardt to pursue the company's strategic initiatives with respect to strengthening and broadening the Company's technologies. To this end, he has resigned from the Board of Directors.

Of his more focused position, Howard Leonhardt goes on to say:

"As Founder, Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board I will remain fully dedicated to assuring that our products are superior to all others in treating and caring for heart failure patients and will continue to be the Company's ambassador in developing relationships worldwide with heart failure physicians."

Mr. Leonhardt emphasized that Bioheart is, in truth, "fully committed to being the 'Go To Technology Partner for Heart Failure Specialists and Their Patients.'"

About Bioheart, Inc.

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derive
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
2. Bioheart, Inc. Announces Additional Funding Support
3. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
4. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
5. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
6. Bioheart, Inc. Announces Results of Annual Meeting
7. Bioheart, Inc., Announces Management Change
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
10. Bioheart, Inc., Added to Russell Microcap Index
11. Bioheart, Inc. to Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... MacroGenics, Inc. announced today that Mr. Paulo F. Costa has ... Mr. Costa is the former President and Chief Executive ... years of experience in operations and commercialization in the pharmaceutical ... , , "We are privileged to have Mr. Costa ...
... VIENNA, Austria, June 23 MIG Fonds and AFFiRiS ... Private Equity Award,competition, hosted by the industry magazine Boerse-Express and ... fund and the Austrian biotechnology company as well as a ... Last Tuesday MIG Fonds and AFFiRiS AG ...
... Denosumab Data , , THOUSAND OAKS, Calif., June 22 ... announced that the U.S. Food and Drug Administration (FDA) has ... Reproductive Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. ... (BLA) for denosumab, a RANK Ligand inhibitor for which Amgen ...
Cached Biology Technology:Paulo F. Costa Joins MacroGenics Board of Directors 2Paulo F. Costa Joins MacroGenics Board of Directors 3AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 2Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 4Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 5Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 6Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 7
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... could benefit from drinking diet soda. New research from ... citrate and malate content in commonly consumed sodas may ... The study was presented at the 104th Annual Scientific ... Increased alkalinity is proven to augment citraturia, a known ...
... a novel approach for thwarting the relentless bacterial infections ... fibrosis (CF), unlocking new possibilities against a tenacious and ... a mainstay antibiotic with drugs to deprive the bacteria ... boost infection killing, they found. Their research, reported ...
... has a soundtrack. Its tempo and tone will vary, ... the brain itself. When that soundtrack is recorded and ... -- it may sharpen their reflexes during a crisis, and ... influence of music on cognitive development, learning, and emotional well-being ...
Cached Biology News:Two-pronged model could help foil tough cystic fibrosis infections 2Two-pronged model could help foil tough cystic fibrosis infections 3Brain music 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
...
Biology Products: